This Week: Off-Label = Off the Rails? Prices Are Out, But Who’s Priced Out? Oregon’s Psilocybin Training Programs Guest Commentary from Sandeep Nayak (Johns Hopkins), who shares his reanalysis of the NEJM psilocybin vs. escitalopram trial NIH Responds to Senators’ Questions on Psychedelic Research California’s Decrim. Bill is Back on the Agenda and more… Off-Label = Off the Rails?


Previous articlePT333 – Miriam Volat, MS & T. Cody Swift, MFT – Conservation, Peyote, and Indigenous Biocultural Survival
Next articlePharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch